Results 101 to 110 of about 276,512 (289)

Post‐Exposure Hepatitis B‐Treatment in Newborns: A Qualitative Study on Interprofessional Practices in Norway

Acta Paediatrica, EarlyView.
ABSTRACT Aim Children born to mothers with chronic Hepatitis B virus (HBV) infection are at substantial risk of developing chronic HBV‐infection without appropriate perinatal post‐exposure treatment. This study aimed to explore midwives' and public health nurses' (PHNs) experiences with HBV‐post‐exposure treatment for infants and identify factors ...
Brita Askeland Winje, Kristine Follstad, Ida Ueland, Signe Zenia Hulgaard‐Bruvold, Margrethe Greve‐Isdahl   +4 more
wiley   +1 more source

Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction. [PDF]

Hum Vaccin Immunother, 2023
Wang X, Xu W, Hu Y, Yao H, Xu L, Ma M, Zhang Y, Wang Y.   +7 more
europepmc   +1 more source

Assessing Risk Thresholds in Controlled Human Infection Models (CHIM)

Bioethics, EarlyView.
ABSTRACT Controlled Human Infection Models (CHIMs) are a type of clinical trial involving deliberately exposing human volunteers to an infectious agent. Compared to studies of natural infection, CHIMs offers distinctive benefits, from the ability to study presymptomatic infection to a direct assessment of the efficacy of vaccines and therapeutics in a ...
Alexa Nord‐Bronzyk, Barnaby Young, Jerry Menikoff, Julian Savulescu, G. Owen Schaefer   +4 more
wiley   +1 more source

Hepatitis A and Hepatitis B Vaccination Responses in Persons with Chronic Hepatitis C Infections: A Review of the Evidence and Current Recommendations

Canadian Journal of Infectious Diseases and Medical Microbiology, 2008
In persons with chronic hepatitis C virus (HCV) infections, superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) can cause serious complications, including fulminating hepatitis or increased severity of hepatitis.
Jane A Buxton, Jin Hee Kim
doaj   +1 more source

Common Genetic Variants of Response to Hepatitis B Vaccines Correlate with Risks of Chronic Infection of Hepatitis B Virus: A Community-Based Case-Control Study. [PDF]

Int J Mol Sci, 2023
Wu TW, Chou CL, Chen CF, Wang LY.
europepmc   +1 more source

[Hepatitis B vaccines-history, achievements, challenges, and perspectives]. [PDF]

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2022
Gerlich WH.
europepmc   +1 more source

Evidence‐ and consensus‐based guideline on lichen sclerosus

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The German‐language, consensus‐ and evidence‐based S3 guideline on lichen sclerosus (LS) was developed based on the European “EuroGuiDerm Guideline on lichen sclerosus” under the leadership of the German Dermatological Society (DDG) and the German Society for Gynecology and Obstetrics (DGGG).
Gudula Kirtschig, Linn Woelber, Andreas Günthert, Karl Becker, Alexandra Ciresa‐König, Bettina Fischer, Susanne Fricke‐Otto, Claudia Günther, Christine Hirchenhain, Narayani Helga Köllmann, Alexander Kreuter, Bartosz Malisiewicz, Felix Neis, Dan mon O'Dey, Hagen Ott, Martin Promm, Regina Renner, Anne‐Rose Schardt, Ines Schweizer, Raimund Stein, Jan Ter‐Nedden, Gerda Trutnovsky, Agnes Wand, Gerhard Weyandt, Ricardo N. Werner, Maria Kinberger   +25 more
wiley   +1 more source

Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines. [PDF]

Sci Rep, 2021
Nishida N, Sugiyama M, Ohashi J, Kawai Y, Khor SS, Nishina S, Yamasaki K, Yazaki H, Okudera K, Tamori A, Eguchi Y, Sakai A, Kakisaka K, Sawai H, Tsuchiura T, Ishikawa M, Hino K, Sumazaki R, Takikawa Y, Kanda T, Yokosuka O, Yatsuhashi H, Tokunaga K, Mizokami M.   +23 more
europepmc   +1 more source

Protein nanoparticles assemble in plants, display antigenic viral peptides, and produce an epitope‐specific immune response

The FEBS Journal, EarlyView.
Current methods to control porcine reproductive and respiratory syndrome, a disease affecting pigs, are insufficient and a safer, more effective vaccine is needed. This study describes the design and plant production of a self‐assembling protein nanoparticle vaccine candidate against this disease.
Jordan T. VanderBurgt, Richard Strasser, Hong Zhu, Angelo Kaldis, Christopher P. Garnham, Rima Menassa   +5 more
wiley   +1 more source

Mission 2030: Toward universal hepatitis B immunization

Human Vaccines & Immunotherapeutics
Despite the availability of efficacious and safe vaccines for more than 40 years, the rate of new hepatitis B virus (HBV) infections remains high, leaving large populations at risk of developing chronic hepatitis B, liver cirrhosis and cancer.
Elias Broeckhoven, Kai Dallmeier
doaj   +1 more source